Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

被引:69
作者
Schlienger, RG
Jick, H
Meier, CR
机构
[1] Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Basel Pharmacoepidemiol Unit, CH-4031 Basel, Switzerland
[2] Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA USA
关键词
aspirin; case-control study; inflammation; myocardial infarction; non-steroidal anti-inflammatory agents;
D O I
10.1046/j.1365-2125.2002.01637.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Aspirin decreases the risk of clinical manifestations of atherothrombosis. This effect is mainly due to inhibition of platelet aggregation and potentially due to anti-inflammatory properties of aspirin. To evaluate whether use of non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may also be associated with a decreased risk of first-time acute myocardial infarction (AMI), we performed a population-based case-control analysis using the United Kingdom-based General Practice Research Database (GPRD) Methods We identified first-time AMI-patients free of preexisting diagnosed cardiovascular or metabolic diseases. We compared use of NSAIDs prior to the index date between cases and control patients who were matched to cases on age, gender, practice and calendar time. Results A total of 3319 cases (less than or equal to75 years) with a diagnosis of first-time AMI between 1992 and 1997 and 13139 controls (matched to cases on age, sex, general practice attended, calendar time, years of prior history in the GPRD) were included. Overall, the relative risk estimate of AMI (adjusted for smoking, body mass index, hormone replacement therapy and aspirin) in current NSAID users was 1.17 (95% CI 0.99, 1.37). Long-term current NSAID use (greater than or equal to30 prescriptions) yielded an adjusted odds ratio (OR) of 1.20 (95% CI 0.94, 1.55). Stratification by age (<65 years vs greater than or equal to65 years) and sex did not materially change the results. Conclusions Our findings indicate that current NSAID exposure in patients free of diagnosed cardiovascular or metabolic conditions predisposing to cardiovascular diseases does not decrease the risk of AMI.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 30 条
  • [1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [2] Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
    Baker, CSR
    Hall, RJC
    Evans, TJ
    Pomerance, A
    Maclouf, J
    Creminon, C
    Yacoub, MH
    Polak, JM
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) : 646 - 655
  • [3] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [4] NAPROXEN UP TO DATE - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY AND USE IN RHEUMATIC DISEASES AND PAIN STATES
    BROGDEN, RN
    HEEL, RC
    SPEIGHT, TM
    AVERY, GS
    [J]. DRUGS, 1979, 18 (04) : 241 - 277
  • [5] Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
    Cryer, B
    Feldman, M
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 104 (05) : 413 - 421
  • [6] Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald, GA
    Patrono, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) : 433 - 442
  • [7] A database worth saving
    Jick, H
    [J]. LANCET, 1997, 350 (9084) : 1045 - 1046
  • [8] VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM
    JICK, H
    JICK, SS
    DERBY, LE
    [J]. BRITISH MEDICAL JOURNAL, 1991, 302 (6779) : 766 - 768
  • [9] Jick H, 1996, PHARMACOTHERAPY, V16, P321
  • [10] Principles of epidemiological research on adverse and beneficial drug effects
    Jick, H
    García-Rodríguez, LA
    Pérez-Gutthann, S
    [J]. LANCET, 1998, 352 (9142) : 1767 - 1770